GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cullinan Therapeutics Inc (NAS:CGEM) » Definitions » Current Ratio

Cullinan Therapeutics (Cullinan Therapeutics) Current Ratio : 17.07 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Cullinan Therapeutics Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Cullinan Therapeutics's current ratio for the quarter that ended in Dec. 2023 was 17.07.

Cullinan Therapeutics has a current ratio of 17.07. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Cullinan Therapeutics's Current Ratio or its related term are showing as below:

CGEM' s Current Ratio Range Over the Past 10 Years
Min: 14.82   Med: 23.17   Max: 39.67
Current: 17.07

During the past 6 years, Cullinan Therapeutics's highest Current Ratio was 39.67. The lowest was 14.82. And the median was 23.17.

CGEM's Current Ratio is ranked better than
91.07% of 1556 companies
in the Biotechnology industry
Industry Median: 3.765 vs CGEM: 17.07

Cullinan Therapeutics Current Ratio Historical Data

The historical data trend for Cullinan Therapeutics's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cullinan Therapeutics Current Ratio Chart

Cullinan Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial 39.67 14.82 25.25 21.09 17.07

Cullinan Therapeutics Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.09 15.25 25.32 20.33 17.07

Competitive Comparison of Cullinan Therapeutics's Current Ratio

For the Biotechnology subindustry, Cullinan Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cullinan Therapeutics's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cullinan Therapeutics's Current Ratio distribution charts can be found below:

* The bar in red indicates where Cullinan Therapeutics's Current Ratio falls into.



Cullinan Therapeutics Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Cullinan Therapeutics's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=480.191/28.137
=17.07

Cullinan Therapeutics's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=480.191/28.137
=17.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cullinan Therapeutics  (NAS:CGEM) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Cullinan Therapeutics Current Ratio Related Terms

Thank you for viewing the detailed overview of Cullinan Therapeutics's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cullinan Therapeutics (Cullinan Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
One Main Street, Suite 520, Cambridge, MA, USA, 02142
Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.
Executives
Nadim Ahmed director, officer: President and CEO C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Jacquelyn L Sumer officer: Chief Legal Officer C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Jeffrey Alan Jones officer: Chief Medical Officer ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Jennifer Michaelson officer: See Remarks C/O CULLINAN MANAGEMENT, INC., ONE MAIN STREET SUITE 520, CAMBRIDGE MA 02142
Jeffrey Trigilio officer: Chief Financial Officer C/O CULLINAN MANAGEMENT, INC., ONE MAIN STREET, SUTIE 520, CAMBRIDGE MA 02142
David P. Ryan director C/O CULLINAN ONCOLOGY, INC., ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Vision Scs F2 10 percent owner 74 GRAND RUE, LUXEMBURG N4 L-1660
Savill Corrine officer: Acting Chief Business Officer C/O CULLINAN ONCOLOGY, LLC, ONE MAIN STREET SUITE 520, CAMBRIDGE MA 02142
F2 Bioscience I 2017 Ltd 10 percent owner 8, RUE SAINT-LEGER, GENEVA V8 CH 1205
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Anne-marie Martin director ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104

Cullinan Therapeutics (Cullinan Therapeutics) Headlines

From GuruFocus

Cullinan Oncology to Participate in Upcoming Investor Conferences

By Value_Insider Value_Insider 11-01-2022